Tom Wilbur is Director of Public Affairs at PhRMA focusing on federal advocacy priorities including Medicare and intellectual property. Prior to joining PhRMA, Tom worked in politics and on Capitol Hill, most recently responsible for communications and strategy for U.S. Rep. Fred Upton and the House Energy and Commerce Committee. Tom is a proud Michigander and outside of the office enjoys reading, running, hiking, golfing, live music, and spending time with family and friends.
Recent Posts
National Medicare Education Week: The history of Medicare Part D
By Tom Wilbur | September 15, 2020
Today, in honor of National Medicare Education Week, we’ll be taking a quick look back at the history of Medicare, specifically the Medicare Part D prescription drug benefit .
Read More
The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development
By Tom Wilbur | September 8, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...
Read More
How Medicare Part D supports patients
By Tom Wilbur | September 1, 2020
Since 2006, Medicare Part D has offered seniors and people living with disabilities affordable access to life-saving treatments through comprehensive prescription drug coverage. The benefit has...
Read More
The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development
By Tom Wilbur | August 24, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...
Read More
Supporting access to vaccines for Part D beneficiaries
By Tom Wilbur | August 12, 2020
Today, in honor of National Immunization Awareness Month, we’ll take a look at how Medicare Part D supports access to critical vaccines and strengthens public health. Vaccines represent some of...
Read More
Medicare’s 55th anniversary: Celebrating the success of Part D
By Tom Wilbur | July 30, 2020
Today, we are excited to bring you a special edition of our Medicare Catalyst series in honor of Medicare’s 55th anniversary. On this date in 1965, President Lyndon B. Johnson signed into law...
Read More
The latest: What they are saying: intellectual property protections critical as we work to defeat COVID-19
By Tom Wilbur | July 22, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...
Read More
Three reasons why MedPAC’s latest Part D proposal would be bad for patients
By Tom Wilbur | July 14, 2020
The recently released Medicare Payment Advisory Commission’s (MedPAC) report to Congress recommends restructuring the Medicare Part D benefit and allowing plans greater flexibility to implement...
Read More
The latest: What they are saying: Importance of intellectual property protections to combat COVID-19
By Tom Wilbur | July 2, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...
Read More
The latest: What they are saying: Intellectual property protections critical as we work to defeat COVID-19
By Tom Wilbur | June 5, 2020
The U.S. biopharmaceutical industry depends on reliable intellectual property (IP) protections to promote the development of new treatments and cures for patients. Strong IP protections are...
Read More
Medicare Monday (100)
340B Spotlight (43)
Cost & Consequence (0)
